Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to look at the effectiveness of an anti-HIV drug combination that adds capravirine in patients who have failed their first drug combination treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Agouron Pharmaceuticals
• Treatments: Capravirine; Nelfinavir; Reverse Transcriptase Inhibitors

Criteria

Inclusion Criteria

Patients may be eligible for this trial if they:

• Are HIV-positive.

• Have a CD4 cell count more than 50/mm3.

• Are at least 18 years old.

• Have adequate blood, kidney, and liver functions.

• Are currently taking an anti-HIV drug combination of an NNRTI plus 1 or more NRTIs for more than 28 days and are failing that combination.

Exclusion Criteria

Patients will not be eligible for this trial if they:

• Have had any protease inhibitor or capravirine treatment.

• Have been given any drug that interferes with their immune system or with the study drugs within 28 days of study entry.

• Have had radiation therapy within 28 days of study entry.